Clearside Biomedical, Inc. announced that it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD). Topline data results are expected in the third quarter of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +6.35% | +2.29% | +14.53% |
Apr. 16 | Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors | CI |
Mar. 18 | Clearside Biomedical Names Victor Chong Chief Medical Officer | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.53% | 100M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD